ESTABLISHMENT AND CHARACTERIZATION OF A NEW HUMAN PANCREATIC CANCER CELL LINE CAPAN-26

Eglė Žalytė1, Kęstutis Strupas2, Mindaugas Valius1

1 Institute of Biochemistry, Proteomics Center, Vilnius University Life Sciences Center, Vilnius, Lithuania

2 Institute of Clinical Medicine, Clinic of Gastroenterology, Nephrourology and Surgery, Faculty of Medicine, Vilnius University, Vilnius, Lithuania

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest forms of human cancer. It is basically resistant to all mainstream cancer treatment modalities, such as chemotherapy and radiotherapy, and a surgical resection is effective for only 15-25% of patients [1]. A key to a successful therapy could be individualized treatment, which employs new pancreatic cancer cell lines, derived from patient tissue. Such lines represent a clinically relevant in vitro model of a tumor and can be used for drug testing.

In this study we present a new pancreatic cancer cell line Capan-26, which was derived from PDAC tissue of a 65-year old female Lithuanian patient. We determined cell doubling time and showed expression of E-cadherin and two PDAC markers CEACAM6 and CA19-9 in 2D and 3D Capan-26 culture. Ras sequencing detected a point mutation E76→K76, which is claimed to be oncogenic in both in vitro and in vivo PDAC models [2]. We believe that Capan-26 will be a valuable tool for human PDAC studies in the future.


[1] Goodman MD, Saif MW. Adjuvant therapy for pancreatic cancer. JOP: Journal of the pancreas. 2014; 15: 87-90

[2] Guo Z, Lu Y, Oakes S, Britton A, King T, Huang K, Tzenova V, Ferraro J, Apelian D, Franzusoff A. Trans-national patterns of pancreas cancer ras mutations and discovery of a new ras mutation with oncogenic synergy when found with ras codon 12 mutations. American Assotiation for Cancer Research. 2008; 14.